Surgery and chemotherapy for intrahepatic cholangiocarcinoma

被引:75
作者
Morise, Zenichi [1 ]
Sugioka, Atsushi [1 ]
Tokoro, Takamasa [1 ]
Tanahashi, Yoshinao [1 ]
Okabe, Yasuhiro [1 ]
Kagawa, Tadashi [1 ]
Takeura, Chinatsu [1 ]
机构
[1] Fujita Hlth Univ, Sch Med, Dept Surg, 1-98 Dengakugakubo,Kutsukake Cho, Toyoake, Aichi 4701192, Japan
关键词
Intrahepatic cholangiocarcinoma; Surgery; Chemotherapy;
D O I
10.4254/wjh.v2.i2.58
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Cholangiocarcinoma, arising from bile duct epithelium, is categorized into intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC), including hilarcholangiocarcinoma. Recently, there has been a worldwide increase in the incidence and mortality from ICC. Complete surgical resection is the only approach to cure the patients with ICC. However, locoregional extension of these tumors is usually advanced with intrahepatic and lymph-node metastases at the time of diagnosis. Resectability rates are quite low and variable (18%-70%). The five-year survival rate after surgical resection was reported to be 20%-40%. Median survival time after ICC resection was 12-37.4 mo. Only a small number of ICC cases, accompanied with ECC, gall bladder carcinoma, and ampullary carcinoma, have been reported in the studies of chemotherapy due to the rarity of the disease. However, in some reports, significant anti-cancer effects were achieved with a response rate of up to 40% and a median survival of one year. Although recurrence rate after hepatectomy is high for the patients with ICC, the residual liver and the lung are the main sites of recurrence after tentative curative surgical resection. Several patients in our study had a long-term survival with repeated surgery and chemotherapy. Repeated surgery, combined with new effective regimens of chemotherapy, could benefit the survival of ICC patients. (c) 2010 Baishideng. All rights reserved.
引用
收藏
页码:58 / 64
页数:7
相关论文
共 78 条
[1]
Proposal of progression model for intrahepatic cholangiocarcinoma: Clinicopathologic differences between hilar type and peripheral type [J].
Aishima, Shinichi ;
Kuroda, Yousuke ;
Nishihara, Yunosuke ;
Iguchi, Tomohiro ;
Taguchi, Kenichi ;
Taketomi, Akinobu ;
Maehara, Yoshihiko ;
Tsuneyoshi, Masazumi .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2007, 31 (07) :1059-1067
[2]
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma - A north central cancer treatment group phase II trial [J].
Alberts, SR ;
Al-Khatib, H ;
Mahoney, MR ;
Burgart, L ;
Cera, PJ ;
Flynn, PJ ;
Flynn, PJ ;
Finch, TR ;
Levitt, R ;
Windschitl, HE ;
Knost, JA ;
Tschetter, LK .
CANCER, 2005, 103 (01) :111-118
[3]
CPT-11 for bile-duct and gallbladder carcinoma - A phase II north central cancer treatment group (NCCTG) study [J].
Alberts, SR ;
Fishkin, PA ;
Burgart, LJ ;
Cera, PJ ;
Mahoney, MR ;
Morton, RF ;
Johnson, PA ;
Nair, S ;
Goldberg, RM .
JOURNAL OF GASTROINTESTINAL CANCER, 2002, 32 (2-3) :107-114
[4]
Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma:: a GERCOR study [J].
André, T ;
Tournigand, C ;
Rosmorduc, O ;
Provent, S ;
Maindrault-Goebel, F ;
Avenin, D ;
Selle, F ;
Paye, F ;
Hannoun, L ;
Houry, S ;
Gayet, B ;
Lotz, JP ;
de Gramont, A ;
Louvet, C .
ANNALS OF ONCOLOGY, 2004, 15 (09) :1339-1343
[5]
Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy [J].
Bismuth, H ;
Adam, R ;
Levi, F ;
Farabos, C ;
Waechter, F ;
Castaing, D ;
Majno, P ;
Engerran, L .
ANNALS OF SURGERY, 1996, 224 (04) :509-520
[6]
Hepatic resection and transplantation for peripheral cholangiocarcinoma [J].
Casavilla, FA ;
Marsh, JW ;
Iwatsuki, S ;
Todo, S ;
Lee, RG ;
Madariaga, JR ;
Pinna, A ;
Dvorchik, I ;
Fung, JJ ;
Starzl, TE .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 1997, 185 (05) :429-436
[7]
Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas [J].
Chen, JS ;
Jan, YY ;
Lin, YC ;
Wang, HM ;
Chang, WC ;
Liau, CT .
ANTI-CANCER DRUGS, 1998, 9 (05) :393-397
[8]
Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas [J].
Chen, JS ;
Lin, YC ;
Jan, YY ;
Liau, CT .
ANTI-CANCER DRUGS, 2001, 12 (04) :339-343
[9]
Chen M F, 1999, J Hepatobiliary Pancreat Surg, V6, P136, DOI 10.1007/s005340050096
[10]
Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma [J].
Cho, JY ;
Paik, YH ;
Chang, YS ;
Lee, SJ ;
Lee, DK ;
Song, SY ;
Chung, JB ;
Park, MS ;
Yu, JS ;
Yoon, DS .
CANCER, 2005, 104 (12) :2753-2758